Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459537 | 0.89 | SMN1; SMN2 (0.40) | ALDH1A1LMNAHPGDMAPK1HSD17B10 | |
| SCHEMBL1458796 | 0.87 | GSK3B (0.34) | KDM4EALDH1A1HPGDHSD17B10PTGS2 | |
| SCHEMBL14844251 | 0.85 | CYP2A6 (0.47) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL1459841 | 0.84 | CYP2A6 (0.42) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL1460033 | 0.82 | KLK3 (0.32) | CYP2C9CYP2C19KDM4EALDH1A1HPGD | |
| SCHEMBL1459578 | 0.80 | PTGS2 (0.46) | HTR6KDM4ELMNAPTGS2F2 | |
| SCHEMBL1459530 | 0.75 | SMN1; SMN2 (0.45) | ALDH1A1PTGS2 | |
| SCHEMBL1460054 | 0.73 | TGFBR1 (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL12744791 | 0.72 | CYP2C9 (0.54) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL1459533 | 0.70 | GSK3B (0.36) | ALDH1A1HPGDMAPK1HSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092444-A1 | DIAZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | CYP2A6 1523/4885CYP2E1 1369/4885CYP2C9 2005/4885 |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | ORAI2, ORAI1, RYR2 | CYP2A6 1792/4885CYP2E1 2021/4885CYP2C9 2999/4885 |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | CYP2A6 1487/4885CYP2E1 1805/4885CYP2C9 3333/4885 |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | ORAI1, CACNA1E, RYR2 | CYP2A6 1490/4885CYP2E1 1947/4885CYP2C9 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.